지혈제 및 조직 봉합제 시장 세계 시장 규모는 2024년 73억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 125억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 5.89%를 보일 것으로 전망합니다. 이 시장은 수술 건수 증가, 제품의 유효성, 안전성, 사용 편의성을 향상시키는 기술 발전, 심혈관 질환, 암, 당뇨병과 같은 만성 질환의 유병률 증가 등을 배경으로 꾸준한 성장세를 보이고 있습니다.
시장의 성장과 저침습(MI) 수술에 대한 선호도 증가와 정부의 적극적인 노력으로 시장은 완만한 성장세를 보이고 있습니다.
기술 발전: 첨단 생체 재료, 전달 시스템, 지혈 특성의 개선이 시장 성장을 가속하고 있습니다.
산업용도: 지혈제 및 조직 봉합제는 심혈관, 정형외과 등 다양한 수술에 적용되고 있습니다.
지역별 동향 : 북미는 고도의 의료 기술과 숙련된 의료 전문가를 이용할 수 있는 고도로 발달된 의료 인프라의 존재로 인해 시장을 선도하고 있습니다. 그러나 아시아태평양은 의료 인프라의 개선으로 인해 급성장하는 시장으로 부상하고 있습니다.
경쟁 구도 : 주요 업체들은 제품의 효능, 안전성, 유용성을 높이기 위해 새로운 생체재료, 연구개발, 전달시스템 개발에 투자하고 있습니다.
과제와 기회: 이 시장은 제품 안전에 대한 우려와 같은 문제에 직면하고 있지만, 미충족 의료 수요에 대한 관심이 높아진다는 점에서 기회를 맞이하고 있습니다.
미래 전망: 노인 인구가 증가함에 따라 지혈제 및 조직 봉합제 시장의 미래는 유망합니다. 또한, 비용 효율성과 가치에 기반한 치료에 대한 요구가 증가함에 따라 시장 성장을 가속할 것으로 예측됩니다.
수술 건수 증가
세계 대중의 수술 건수가 증가함에 따라 지혈제 및 조직 봉합제 시장의 성장을 뒷받침하고 있습니다. 사람들은 외과적 개입이 필요한 다양한 질병을 앓고 있습니다. 지혈제 및 조직 봉합제는 일상적인 시술에서 복잡한 수술에 이르기까지 다양한 외과적 개입에서 출혈을 조절하고 치유를 촉진하는 데 필수적입니다. 또한, 출혈성 합병증에 대처하고 환자 결과를 개선하기 위한 효과적인 지혈 및 봉합 솔루션에 대한 수요가 증가함에 따라 시장 성장을 가속하고 있습니다. 복잡한 수술의 경우, 조직 박리 및 조작이 복잡해지면서 출혈성 합병증의 위험이 높아지는 경우가 많습니다. 지혈제 및 조직 봉합제는 이러한 문제를 해결하고 성공적인 수술 결과를 달성하는 데 중요한 역할을 합니다. 또한, 복강경 및 로봇 보조 수술과 같은 MI 수술에 대한 선호도가 높아지면서 시장 성장에 기여하고 있으며, MI 수술은 외상 감소 및 회복 시간 단축 등의 이점이 있지만, 효과적인 지혈 및 조직 밀봉이 여전히 필요하며, 이는 특수 제품을 통해 촉진됩니다. 촉진됩니다.
기술적 진보
지혈제 및 조직 봉합제의 기술 혁신은 제품의 유효성, 안전성 및 사용 편의성을 향상시키는 데 도움이 되고 있습니다. 이러한 발전에는 새로운 생체 재료의 개발, 첨단 전달 시스템 개발, 지혈 특성 향상 등이 포함됩니다. 또한, 우수한 응고 메커니즘을 가진 지혈제와 접착력이 강화된 조직 봉합제의 도입으로 더 나은 지혈과 상처 봉합이 가능해졌습니다. 생체적합성 재료와 생분해성 제제의 발전은 조직 적합성 및 장기 안전성에 대한 우려를 해소할 수 있습니다. 또한, 새로운 전달 시스템을 통해 지혈제 및 조직 봉합제를 수술 부위에 정확하게 적용할 수 있게 되었습니다. 이러한 시스템에는 스프레이 어플리케이터, 주사제 또는 약물의 제어된 표적 전달을 가능하게 하는 특수 장치가 포함됩니다. 표적 전달 시스템은 수술 효율을 개선하고, 낭비를 최소화하며, 지혈 및 조직 봉합제의 효과를 향상시킵니다. 또한, 생분해성 지혈 및 조직 봉합제는 시간이 지남에 따라 분해되어 체내에 흡수되도록 설계되어 별도의 제거나 개입이 필요하지 않습니다.
만성질환 증가
심혈관 질환, 암, 당뇨병과 같은 만성 질환 증가는 지혈 및 조직 봉합제에 대한 수요를 자극하고 있습니다. 만성질환은 진단, 치료, 관리를 위해 외과적 수술이 필요한 경우가 많습니다. 생활습관, 환경적 요인, 식습관의 변화로 인해 이러한 질병에 걸리는 사람이 증가하고 있습니다. 당뇨병성 궤양, 욕창, 정맥성 궤양과 같은 만성 상처는 만성 질환의 흔한 합병증으로, 종종 드레싱, 상처 봉합 및 관리를 위한 외과적 개입이 필요합니다. 이러한 절차에서는 지혈을 촉진하고, 상처 봉합을 용이하게 하고, 치유를 촉진하기 위해 지혈제 및 조직 봉합제를 사용합니다. 이와는 별도로, 만성 질환 환자는 출혈 및 상처 치유 문제를 포함한 수술 합병증의 위험을 증가시키는 동반 질환 및 생리적 장애를 나타낼 수 있습니다. 지혈제 및 조직 봉합제는 출혈을 조절하고 조직을 밀봉하며 최적의 상처 치유를 촉진함으로써 이러한 위험을 줄이는 데 중요한 역할을 하고 있으며, 이는 시장 성장을 뒷받침하고 있습니다.
The global hemostasis and tissue sealing agents market size reached USD 7.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.5 Billion by 2033, exhibiting a growth rate (CAGR) of 5.89% during 2025-2033. The market is experiencing steady growth driven by rising number of surgical procedures, technological advancements leading to enhanced product efficacy, safety, and ease of use, and increasing prevalence of chronic diseases, such as cardiovascular ailments, cancer, and diabetes.
Market Growth and Size: The market is witnessing moderate growth on account of increasing preferences for minimally invasive (MI) surgeries, along with favorable governing initiatives.
Technological Advancements: Advanced biomaterials, delivery systems, and improved hemostatic properties are propelling the market growth.
Industry Applications: Hemostasis and tissue sealing agents find applications across a wide range of surgical procedures, including cardiovascular and orthopedic.
Geographical Trends: North America leads the market, driven by the presence of highly developed healthcare infrastructure with access to advanced medical technologies and skilled healthcare professionals. However, Asia Pacific is emerging as a fast-growing market due to the improving healthcare infrastructure.
Competitive Landscape: Key players are investing in research and development (R&D) activities to explore novel biomaterials, formulations, and delivery systems for enhancing product efficacy, safety, and usability.
Challenges and Opportunities: While the market faces challenges, such as product safety concerns, it also encounters opportunities on account of the rising focus on addressing unmet medical needs.
Future Outlook: The future of the hemostasis and tissue sealing agents market looks promising with the increasing geriatric population. In addition, the rising need for cost-effectiveness and value-based care is anticipated to bolster the market growth.
Rising number of surgical procedures
The increasing number of surgical procedures among the masses across the globe is supporting the hemostasis and tissue sealing agents market growth. People are suffering from various diseases that require surgical intervention. Hemostasis and tissue sealing agents are vital for controlling bleeding and promoting healing during various surgical interventions, ranging from routine procedures to complex surgeries. Additionally, the rising need for effective hemostatic and sealing solutions to address bleeding complications and enhance patient outcomes is propelling the market growth. Complex surgeries often involve intricate tissue dissection and manipulation, leading to a higher risk of bleeding complications. Hemostasis and tissue sealing agents play a critical role in addressing these challenges and ensuring successful outcomes. Furthermore, increasing preferences for MI surgical techniques, such as laparoscopic and robotic-assisted procedures, are contributing to the market growth. While MI surgeries offer benefits like reduced trauma and faster recovery times, they still require effective hemostatic control and tissue sealing, which are facilitated by specialized products.
Technological Advancements
Technological innovations in hemostasis and tissue sealing agents assist in enhancing product efficacy, safety, and ease of use. These advancements include the development of novel biomaterials, advanced delivery systems, and improved hemostatic properties. Moreover, the introduction of hemostatic agents with superior clotting mechanisms and tissue sealants with enhanced adhesive properties enable better hemostasis and wound closure. Advancements in biocompatible materials and biodegradable formulations address concerns regarding tissue compatibility and long-term safety. Furthermore, novel delivery systems enable the precise application of hemostasis and tissue sealing agents to the surgical site. These systems include spray applicators, injectable formulations, or specialized devices that allow for controlled and targeted delivery of the agents. Targeted delivery systems improve surgical efficiency, minimize wastage, and enhance the effectiveness of hemostasis and tissue sealing agents. Besides this, biodegradable hemostasis and tissue sealing agents are designed to degrade over time and be absorbed by the body, eliminating the need for subsequent removal or intervention.
Increasing prevalence of chronic diseases
The growing prevalence of chronic diseases, such as cardiovascular ailments, cancer, and diabetes, is catalyzing demand for hemostasis and tissue sealing agents. Chronic conditions often require surgical procedures for diagnosis, treatment, or management. People are increasingly suffering from these diseases due to changing lifestyles, environmental factors, and eating habits. Chronic wounds, such as diabetic ulcers, pressure ulcers, and venous ulcers, are common complications of chronic diseases and often require surgical intervention for debridement, closure, or management. Hemostasis and tissue sealing agents are utilized in these procedures to promote hemostasis, facilitate wound closure, and accelerate healing. Apart from this, patients with chronic diseases may present with comorbidities or physiological impairments that increase the risk of surgical complications, including bleeding and wound healing issues. Hemostasis and tissue sealing agents play a critical role in mitigating these risks by controlling bleeding, sealing tissues, and promoting optimal wound healing, which is supporting the market growth.
Topical hemostats account for the majority of the market share
Topical hemostats are agents applied directly to the bleeding site to control bleeding. They are available in various forms, such as powders, gels, sponges, and patches. These hemostats work by promoting coagulation, accelerating clot formation, or enhancing platelet aggregation to achieve hemostasis. They are particularly useful in surgical procedures where direct pressure or conventional methods may not be sufficient to achieve hemostasis.
Adhesive and tissue sealant products are used to seal tissues, close wounds, or bond tissues together. They are available in liquid, gel, or film forms and are applied directly to the tissue surface. These products contain biocompatible materials that adhere to the tissue surface and create a barrier, promoting wound healing and preventing leakage or further bleeding.
Collagen-based hemostats utilize collagen, a protein found in connective tissues. Collagen promotes platelet adhesion and activation, initiating the clotting cascade to achieve hemostasis. Collagen-based hemostats are available in various forms, such as sponges, powders, or patches, and are widely used in surgical procedures across different specialties.
Oxidized regenerated cellulose (ORC) based hemostats are derived from cellulose, a polysaccharide found in plants. Through a process of oxidation and regeneration, cellulose is converted into ORC, which possesses hemostatic properties. ORC-based hemostats work by promoting platelet aggregation and accelerating clot formation at the bleeding site. They are available in different forms like gauzes, pads, or powders and are commonly used in surgeries where rapid hemostasis is required.
Gelatin-based hemostats are derived from collagen obtained from animal sources, usually bovine or porcine. Gelatin possesses hemostatic properties and is often combined with thrombin or other clotting factors to enhance its efficacy. These hemostats come in various forms, such as sponges, powders, or sheets, and are used in surgical procedures to control bleeding and promote wound healing.
Polysaccharide-based hemostats utilize polysaccharides, complex carbohydrates found in plants or animals. These hemostats work by promoting platelet activation and aggregation, facilitating clot formation. Polysaccharide-based hemostats include products derived from substances like chitosan, alginate, or starch. They are available in different forms like powders, gels, or films and are utilized in surgical procedures to achieve hemostasis and promote tissue sealing.
General surgery represents the leading market segment
General surgery encompasses a wide range of surgical procedures involving various organs and tissues within the body. These surgeries can include procedures, such as appendectomies, hernia repairs, gallbladder removals, and bowel surgeries. Hemostasis and tissue sealing agents play a crucial role in general surgery by controlling bleeding, sealing tissues, and promoting wound healing. These agents are used to manage bleeding from incisions, dissected tissues, and damaged vessels, ensuring optimal surgical outcomes and patient recovery.
Minimally invasive surgery (MIS), also known as laparoscopic or keyhole surgery, involves performing surgical procedures through small incisions using specialized instruments and a camera for visualization. MIS offers several advantages as compared to traditional open surgery, such as reduced post-operative pain, shorter hospital stays, and quicker recovery times. In minimally invasive (MI) procedures, hemostasis and tissue sealing agents are essential for controlling bleeding and sealing tissues through small incisions. These agents are applied directly to the surgical site to achieve hemostasis and ensure optimal tissue closure.
Hospitals serve as primary settings for a wide range of medical interventions, including surgical procedures requiring hemostasis and tissue sealing agents. These facilities encompass various departments, such as operating rooms, emergency departments, and specialty units, where surgeries are performed. Hospitals have comprehensive resources, including specialized equipment, trained personnel, and integrated healthcare services, making them key users of hemostasis and tissue sealing agents. These agents are used across different surgical specialties within hospital settings to control bleeding, seal tissues, and promote wound healing.
Ambulatory surgical centers (ACSs), also known as outpatient surgery centers or day surgery centers, provide surgical services on an outpatient basis, allowing patients to undergo procedures without overnight hospitalization. ASCs offer a convenient and cost-effective alternative to traditional hospital-based surgeries, particularly for minor or elective procedures. In ASCs, hemostasis and tissue sealing agents are utilized to control bleeding and promote wound closure during various surgical interventions. These centers often specialize in specific surgical specialties, such as ophthalmology, orthopedics, or gastroenterology, where hemostasis and tissue sealing agents are routinely used to ensure safe and efficient surgical outcomes.
Home care settings involve the provision of medical care, including post-operative care, within the home of patients. Hemostasis and tissue sealing agents are used to address wound complications, promote healing, and prevent infections, ensuring continuity of care and facilitating the recovery process of patients within the comfort of their homes.
North America leads the market, accounting for the largest hemostasis and tissue sealing agents market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share due to the presence of highly developed healthcare infrastructure, with access to advanced medical technologies and skilled healthcare professionals. Additionally, the rising number of surgical procedures among individuals is bolstering the market growth.
Asia Pacific stands as another key region in the market, driven by the increasing adoption of MI surgeries among the masses. In addition, improving healthcare infrastructure is contributing to the growth of the market.
Europe maintains a strong presence in the market, with the rising prevalence of chronic diseases among individuals. Besides this, stringent standards for the approval and marketing of medical devices, including hemostasis and tissue sealing agents, are impelling the market growth.
Latin America exhibits the growing potential in the market on account of the increasing need for hemostasis and tissue sealing agents during surgical interventions. Furthermore, the rising awareness among healthcare professionals and patients about the benefits of advanced surgical techniques and medical products is bolstering the market growth.
The Middle East and Africa region is primarily driven by improving healthcare infrastructure. Moreover, thriving medical tourism in the region is propelling the market growth.
Key players are investing in R&D activities to explore novel biomaterials, formulations, and delivery systems to enhance product efficacy, safety, and usability. They are continuously innovating their product offerings to meet the diverse needs of healthcare providers and patients by developing advanced hemostatic agents and tissue sealants with enhanced hemostatic properties, faster sealing times, and improved biocompatibility. In addition, companies are expanding the indications for their hemostasis and tissue sealing agents, making them applicable to a wider range of surgical procedures. This involves obtaining regulatory approvals for new indications and conducting clinical trials to demonstrate product efficacy and safety in different surgical specialties. Furthermore, companies are expanding their market reach by entering new geographical regions.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Advance Medical Solution Group Plc.